Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
INSIGHT PROVIDER
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Message
Follow
Location:
India
Joined:
30 September 2021
640
Insights
234.8k
Views
210
Followers
Health Care
•
Equity Bottom-Up
•
Thematic (Sector/Industry)
Message
Follow
Regions
Sectors
Verticals
More Filters
Refresh
Top Picks Only
Recent
bearish
•
Sumitomo Pharma
•
02 May 2024 18:30
Sumitomo Pharma (4506 JP): FY24 Guidance Revised Lower; Further Cost Cuts in FY25 to Turn Profitable
Sumitomo Pharma raised FY24 operating loss guidance by ¥199B to ¥355B due to impairment loss. The company expects to turn profitable in FY25 via...
Tina Banerjee
26 Views
Share
bullish
•
Peptidream Inc
•
01 May 2024 22:55
Peptidream (4587 JP): Steadily Riding the Next Wave of Drug Discovery
Peptidream got nod for first human trial for radiopharma targeting renal cell carcinoma. Expanded peptide discovery collaboration with Novartis...
Tina Banerjee
162 Views
Share
bearish
•
Ono Pharmaceutical
•
30 Apr 2024 21:12
Ono Pharmaceutical (4528 JP): Deciphera Acquisition Will Not Bring Immediate Respite
Ono Pharmaceutical will acquire Deciphera Pharmaceuticals for $25.60/share in cash. The total equity value of the acquisition is ~$2.4B. The...
Tina Banerjee
253 Views
Share
bullish
•
Indegene Limited
•
29 Apr 2024 15:23
Indegene Limited Pre-IPO: Subscribe on Profitable Niche Business Model and Attractive Valuation
Indegene is raising INR18B via Indian IPO. The IPO consists of fresh issuance of equity shares worth INR7.6B and an OFS of 23.9M equity shares by...
Tina Banerjee
302 Views
Share
bearish
•
Astellas Pharma
•
26 Apr 2024 23:29
Astellas Pharma (4503 JP): Fx Drives FY24 Revenue; Impairment Loss Dents Profits; Pain to Continue
For FY25, Astellas Pharma guided for just 3% revenue growth. FY25 core operating profit is expected to decline 10%, while net profit is anticipated...
Tina Banerjee
404 Views
Share
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.31.0
x